Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a ...

We recently published a list of 10 Stocks Got Wiped Out. Are You Holding Any? In this article, we are going to take a look at ...

Stay on our website for longer than five minutes and you’re bound to find references to Schaeffer’s Volatility Scorecard (SVS ...

Our writer takes a look at three red-hot growth stocks that have more than doubled this year to see if any of them interest ...

Thermo Fisher has unleashed its next-generation TruNarc Delta and Tau Handheld Narcotics Analyzers to help law enforcement ...

Large-cap stocks were the worst performers last week, with declines up to 23%. Reasons include revenue misses, FDA bans, and Uber's stake monetization.

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers Health (HIMS) has captured significant market attention in 2025 with its dramatic stock swings, starting the year ...

About Hims & Hers Health Inc. Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers Health (HIMS) has received mixed ratings from Top Wall Street analysts, with Morgan Stanley (MS) maintaining a Hold rating while Citi (C) reiterates a Sell rating. The company’s strong app ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...